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OBJECTIVES This study aimed to clarify the role of the angiotensin-converting enzyme (ACE) gene
polymorphism in the development of in-stent restenosis.
BACKGROUND In-stent restenosis occurs after treatment of coronary artery stenosis in 12% to 32% of
coronary interventions with stents. Experimental and clinical studies have suggested that the
deletion/insertion (D/I) polymorphism of the ACE gene plays a role in this.
METHODS Quantitative coronary angiography before, immediately after and six months after stent
implantation were compared in 369 patients, in whom D/I typing of the ACE gene was
performed.
RESULTS At follow-up we found no differences between the three genotypes in minimal lumen
diameter (homozygotes with two deletion alleles in the ACE gene [DD], 2.20 mm;
heterozygotes with one deletion and one insertion allele in the ACE gene [DI], 2.19 mm; and
homozygotes with two insertion alleles in the ACE gene [II], 2.25 mm). The corresponding
diameter stenoses were: DD: 25%, DI: 27%, II: 27% (p  NS), and the frequency of
restenosis (50% diameter stenosis) was: DD: 15.7%, DI: 11.0% and II: 16.4% (p  NS).
Logistic regression analysis identified diabetes (odds ratio [OR]: 3.0, 95% confidence interval
[CI]: 1.0 to 8.7), lesion length (OR: 1.1, 95% CI: 1.01 to 1.30) and minimal lumen diameter
immediately after the intervention (OR: 0.3, 95% CI: 0.14 to 0.85) as predictors of in-stent
restenosis. In a post hoc analysis of patients treated versus those not treated with an
ACE-inhibitor antagonist or an angiotensin receptor antagonist, we found an increased
frequency of in-stent restenosis in the DD genotypes (40% vs. 12%, p  0.006).
CONCLUSIONS The D/I polymorphism is not an independent predictor of coronary in-stent restenosis in
general, but it may be of clinical importance in patients treated with ACE inhibitors or
angiotensin receptor antagonists. (J Am Coll Cardiol 2001;38:1434–9) © 2001 by the
American College of Cardiology
Percutaneous coronary intervention with stent implantation
has proved efficient to reduce complications and restenosis
compared with balloon angioplasty alone. The major draw-
back of this technique is intimal hyperplasia developed by
migration and proliferation of cells derived from the vessel
media, a cell growth process that causes significant in-stent
restenosis in 12% to 32% of cases (1–6). The angiotensin-
converting enzyme (ACE) stimulates smooth muscle cell
proliferation (7), and the plasma concentration of the ACE
is partly controlled by a deletion/insertion (D/I) polymor-
phism in the ACE gene on chromosome 17 (8).
Angiotensin-converting enzyme inhibitors have, accord-
ingly, been evaluated as prophylactic treatment against
restenosis in several studies, but no positive effect has been
shown (9–12). Restenosis after balloon angioplasty depends
predominantly on elastic vessel recoil as opposed to in-stent
restenosis, which depends mainly on neointimal growth
(13–15). Thus, the significance of the D/I polymorphism of
the ACE gene might increase with the rate of stent
implantation. This study was undertaken to evaluate the
role of the ACE gene polymorphism for the development of
restenosis after coronary stenting.
METHODS
Patients. Four hundred seventy-three patients, of which
99% were Caucasian Danes with coronary artery disease,
were included in the Danish Randomized Multicenter Trial
of Coronary Restenosis After Treatment with the NIR and
the Palmaz-Schatz Stent (DANSTENT) study from April
1997 through January 2000 (16). The patients had one or
more coronary stents implanted in coronary lesions. Most
patients were treated electively for stable angina. Of the 473
patients, 93% had a follow-up coronary angiography per-
formed six months after stent implantation. Patients sched-
uled to follow up in our lab were entered into this study and
had a blood sample taken for genotyping at the time of the
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follow-up angiography. Thus, all 369 patients in this study
had a follow-up angiogram done. The end points of the
study were clinical and angiographic signs of in-stent
restenosis. The study protocol was approved by our scientific
ethics committee and conformed to the Declaration of
Helsinki.
Coronary artery lesions. Lesion complexity at baseline was
characterized by standard angiographic morphology criteria
(17). One lesion per patient was analyzed in this study, and
only de novo lesions located in native coronary arteries were
included. The length of the lesion should not exceed 28 mm
(to be covered maximally by two stents). Ostial and heavily
calcified lesions were excluded.
Angiographic assessment. Coronary angiography was ac-
quired according to quantitative coronary angiography
(QCA) guidelines before and immediately after angioplasty
and six months later. Patients were positioned with the
index lesion in the isocenter of the X-ray system (C-arm,
Integris System, Philips Medical Systems, Best, the Neth-
erlands), with the image intensifier close to the chest of the
patient. The lesion was visualized in two different projec-
tions when possible, with a minimum of foreshortening and
a minimal overlap of side branches after intracoronary
administration of 0.2-mg nitroglycerin. Identical projec-
tions were used before and after coronary intervention and
at the six-month follow-up angiography. The angiograms
were saved on compact or laser discs. The coronary angio-
grams were analyzed by QCA by an independent core labora-
tory (Heart Core B.V., Leiden, the Netherlands) (18,19). The
core laboratory had no access to clinical or genotype data.
Determination of the ACE D/I genotype. DNA was
extracted from blood, and the D/I polymorphism of the
ACE gene was determined by polymerase chain reaction
amplification of intron 16 of the ACE gene using primers.
All tests apparently homozygous for the D-allele were
controlled for misclassification as previously described
(20,21). The analyzing laboratory (Department of Clinical
Biochemistry, Statens Serum Institut, Copenhagen, Den-
mark) had no access to clinical or angiographic data.
Coronary stenting technique. Lesions were predilated
with a 20-mm long balloon of a diameter close to the
reference diameter of the vessel. A 15-mm Palmaz-Schatz
(Johnson and Johnson Interventional Systems, Warren,
New Jersey) or a 16-mm NIR stent (Medinol Ltd., Tel
Aviv, Israel) was hand crimped onto the balloon and
implanted with high pressure (12 atms). When two stents
were implanted, an overlap of approximately 2 mm was
intended. If necessary, high-pressure postdilation was per-
formed with a noncompliant balloon. Intracoronary ultra-
sound imaging was discouraged.
Study end points and clinical decision making. The
primary end point of the study was coronary restenosis
defined as a diameter stenosis 50% of the index lesion at
follow-up angiography. In addition, we analyzed other
lesion-specific parameters including minimal lumen diam-
eter, diameter stenosis and late lumen loss defined as the
difference between the minimal lumen diameter immedi-
ately after stent implantation and that at six-month follow-
up. We recorded the rate of ischemia driven target lesion
revascularization defined as reangioplasty of the study seg-
ment together with 50% diameter restenosis in combina-
tion with angina pectoris or a pathologic exercise test. In
case of an angiography performed 0 to 4 months after stent
implantation leading to revascularization of the target ves-
sel, the angiogram was evaluated by the core lab. If no
significant restenosis was observed, a repeat angiography
was performed at six months. If a coronary angiography was
performed more than four months after stent implantation,
the six-month angiography was waived. The decision to
perform target lesion revascularization was left to the
discretion of the investigator at the time of reinvestigation.
Statistical analysis. Median values and 5th and 95th per-
centiles were used as descriptive statistics for continuous
variables. Whenever index lesion measurements were avail-
able in two different projections, we used the average values.
Statistical analysis was performed using the chi-square test
(discrete variables) and Kruskal-Wallis test (continuous
variables). Logistic regression models were used to study the
risk of restenosis. We used SAS procedures for statistical
analysis (Freq, Npar1way, Univariate and Logistic; SAS ver-
sion 8.0; 1998, SAS Institute, Cary, North Carolina).
RESULTS
Patients in the DANSTENT study belonged to a low-risk
cohort. In 473 patients, there were a total of three deaths at
six-month follow-up. One patient died of lung cancer, and
two suffered a cardiovascular death. The average age of the
369 patients (24% women) in this study was 59 years (range:
40 to 77 years). There were no differences in baseline
characteristics between the total DANSTENT cohort and
the patients in this study, and the restenosis rates were
12.6% and 13.8%, respectively, with no difference between
patients with or without genotyping (p  0.1). The fre-
quency of the D-allele of the ACE genotype was 0.55, and
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
DANSTENT  Danish Randomized Multicenter Trial
of Coronary Restenosis After
Treatment with the NIR and the
Palmaz-Schatz Stent
DD  homozygotes with two deletion alleles
in the ACE gene
D/I  deletion/insertion
DI  heterozygotes with one deletion and
one insertion allele in the ACE gene
II  homozygotes with two insertion alleles
in the ACE gene
PTCA  percutaneous transluminal coronary
angioplasty
QCA  quantitative coronary angiography
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the frequencies of the DD, DI and II genotypes were 29%,
53% and 18%, respectively. The ACE genotype distribution
was, thus, in Hardy-Weinberg equilibrium and comparable
to those of previous reports (20,21). The clinical, angio-
graphic and procedural baseline characteristics were compa-
rable among the three groups (Table 1).
The frequency of ischemia-driven revascularization of the
study lesion at follow-up after stent implantation did not
differ between the three groups (homozygotes with two
deletion alleles in the ACE gene [DD]: 15%, heterozygotes
with one deletion and one insertion allele in the ACE gene
[DI]: 10%, homozygotes with two insertion alleles in the
ACE gene [II]: 13%, p  NS). Quantitative coronary
angiography at follow-up revealed a 13% restenosis rate for
the whole cohort with no differences in reference diameter,
minimal lumen diameter, diameter stenosis or frequency of
restenosis between the three groups, and there were no
differences in late loss, net gain or loss index (Table 2). The
cumulative distribution curves of the minimal lumen diam-
eter before and after stent implantation and at follow-up
were rather similar between the three groups of patients
(Fig. 1). A logistic regression analysis showed no influence
of ACE genotype and treatment with ACE inhibitors or
angiotensin receptor antagonists on in-stent restenosis, and
no interaction was found between ACE genotype and
treatment with ACE inhibitors or angiotensin receptor
antagonists. The only significant predictors of in-stent
restenosis were a history of diabetes, lesion length before
stent implantation and minimal lumen diameter immedi-
ately after stent implantation (Table 3).
The patients receiving ACE inhibitors or angiotensin
receptor antagonists had more hypertension, diabetes,
three-vessel disease, reduced left ventricular ejection frac-
tion and long lesions than those who did not receive these
drugs. This subset of patients treated with an ACE inhib-
itor/angiotensin receptor antagonist also had a tendency
towards more in-stent restenosis, increased late loss, per-
centage of stenosis and target lesion revascularization at
six-months follow-up. Patients on ACE inhibitor/
angiotensin receptor antagonist treatment with the DD
genotype of the ACE gene had a significantly higher
Table 1. Clinical and Coronary Lesion Characteristics
at Baseline
DD
(n  105)
DI
(n  196)
II
(n  68)
p
Value
Female gender 24 23 29 0.6
Median age, years
(range)
58 (43–73) 60 (45–77) 57 (40–73) 0.1
Unstable angina 17 15 21 0.7
Family history of CAD 40 36 34 0.7
Previous MI 51 49 60 0.3
Tobacco smokers 76 67 75 0.5
Diabetes 11 9 9 0.6
Hypertension 22 27 19 0.3
Hypercholesterolemia 41 42 44 0.9
ACE inhibitor or
AT-2 drugs
14 15 21 0.5
Complex lesions
(B2 or C)
75 70 65 0.3
Variables (except age) in table are percentages.
ACE-1 or AT-2 drugs  patients treated with an angiotensin-converting enzyme
inhibitor or angiotensin-2 receptor antagonist; CAD  coronary artery disease;
complex lesions (B2 or C)  lesion morphology type B2 or C according to the
modified American College of Cardiology/American Heart Association Classification
(36); DD  homozygotes with two deletion alleles in the ACE gene; DI 
heterozygotes with one deletion and one insertion allele in the ACE gene; II 
homozygotes with two insertion alleles in the ACE gene; MI  myocardial
infarction.
Table 2. Core Laboratory Quantitative Coronary Angiography Data
DD
(n  105)
DI
(n  196)
II
(n  68)
p
Value
Lesion length, mm 12.65 (5.74, 22.62) 13.06 (6.03, 22.28) 12.00 (5.40, 28.78) 0.8
Reference diameter, mm
Preprocedure 2.97 (2.22, 4.07) 2.97 (2.26, 3.86) 3.04 (2.24, 4.35) 0.6
Postprocedure 3.24 (2.49, 4.22) 3.17 (2.63, 4.18) 3.23 (2.61, 4.54) 0.8
Follow-up 3.00 (2.39, 3.97) 3.05 (2.38, 4.20) 3.10 (2.48, 4.48) 0.5
Minimal lumen diameter, mm
Preprocedure 1.04 (0, 1.66) 1.03 (0, 1.78) 0.97 (0, 1.88) 0.8
Postprocedure 2.84 (2.27, 3.81) 2.82 (2.22, 3.73) 2.98 (2.32, 3.82) 0.2
Follow-up 2.20 (0.88, 3.31) 2.19 (1.14, 3.38) 2.25 (0.83, 3.44) 0.9
Percent diameter stenosis
Preprocedure 65.3 (47.3, 100) 64.2 (45.8, 100) 66.0 (44.2, 100) 0.8
Postprocedure 10.4 (14.0, 22.3) 10.8 (1.6, 24.8) 8.5 (12.0, 24.0) 0.2
Follow-up 24.9 (6.5, 70.3) 27.2 (6.9, 62.9) 27.3 (7.6, 75.6) 0.6
Restenosis 50% 15.7 11.0 16.4 0.4
Acute gain, mm 1.94 (1.12, 2.93) 1.86 (1.08, 2.88) 2.01 (1.09, 3.08) 0.3
Late loss, mm 0.64 (0.27, 1.97) 0.64 (0.12, 1.71) 0.66 (0, 1.90) 0.5
Net gain, mm 1.25 (0.21, 2.34) 1.24 (0.05, 2.57) 1.32 (0, 2.26) 0.8
Loss index 0.34 (0.12, 1.18) 0.35 (0.09, 0.96) 0.32 (0, 0.87) 0.7
All continuous variables are expressed as median values. The numbers in parentheses are the 5th and 95th percentiles.
Acute gain  Postprocedure minimal lumen diameter minus preprocedure minimal lumen diameter of the coronary lesion;
DD  homozygotes with two deletion alleles in the angiotensin-converting enzyme (ACE) gene; DI  heterozygotes with one
deletion and one insertion allele in the ACE gene; II  homozygotes with two insertion alleles in the ACE gene; Late loss 
Postprocedure minimal lumen diameter minus minimal lumen diameter at follow-up; Loss index  late loss divided by acute
gain; Net gain  minimal lumen diameter at follow-up minus preprocedure minimal lumen diameter.
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in-stent restenosis rate than those without this treatment
(Table 4).
DISCUSSION
ACE gene testing and clinical relevance. Restenosis after
percutaneous coronary interventions has represented a large
clinical problem since the introduction of balloon angio-
plasty, and it remains the major drawback of this technique
even after the introduction of stent implantation (2–6).
Drugs with anti-inflammatory and antiproliferative effects,
drug-eluting stents and brachytherapy are currently the
most promising new techniques to prevent in-stent resten-
osis (22–25). However, toxicity, drug interaction, long-term
efficacy and costs have to be assessed to evaluate the
potentials for routine therapy of these modalities. Thus, a
test that could identify patients with increased risk of
developing in-stent restenosis would be helpful. To our
knowledge, this study is the first to address the ACE gene
polymorphism and coronary in-stent restenosis issue using
QCA analysis performed by an independent core laboratory.
The results of our study, in which the rate of coronary
in-stent restenosis was relatively low, showed that the D/I
polymorphism of the ACE gene had no clinical relevance as
a predictor of in-stent restenosis.
ACE gene polymorphism and in-stent restenosis.
Amant et al. (26) studied the D/I polymorphism of the
ACE gene in 171 patients who underwent percutaneous
transluminal revascularization with stent implantation for
suboptimal balloon results in most cases. In the 146 patients
(85%) who had a six-month follow-up angiography, a
Figure 1. The cumulative distribution curve of minimal lumen diameter in 369 patients before stent implantation (curves at the left), after stent
implantation (curves at the right) and at follow-up (curves in the middle). DD  homozygotes with two deletion alleles in the angiotensin-converting
enzyme (ACE) gene; DI  heterozygotes with one deletion and one insertion allele in the ACE gene; II  homozygotes with two insertion alleles in the
ACE gene.
Table 3. Odds Ratios for In-Stent Restenosis at
Follow-Up Angiography
Odds Ratio 95% CI p Value
Diabetes 3.0 1.0–8.7 0.04
Post PCI MLD (per mm) 0.3 0.14–0.85 0.01
Lesion length (per 2 mm) 1.1 1.01–1.30 0.04
Genotype DD vs. DI vs. II 1.3 0.8–2.4 0.35
Female gender 2.1 1.0–4.6 0.06
Other risk factors tested in model: Age, left ventricular ejection fraction, previous
myocardial infarction, hypertension and treatment with angiotensin-converting en-
zyme (ACE) inhibitors or angiotensin-2 receptor antagonist.
CI  confidence interval; DD  homozygotes with two deletion alleles in the
ACE gene; DI heterozygotes with one deletion and one insertion allele in the ACE
gene; II  homozygotes with two insertion alleles in the ACE gene; MLD 
minimal lumen diameter; PCI  percutaneous coronary intervention.
Table 4. Clinical Characteristics and Quantitative Coronary
Angiography Parameters at Follow-Up of Patients Treated
Versus Those Not Treated With Angiotensin-Converting
Enzyme Inhibitors or Angiotensin Receptor Antagonists
Not Treated
(n  309)
DD 89, DI 166,
II 54
Treated
(n  59)
DD 15, DI 30,
II 14
p
Value
Age, yrs 58 (43, 75) 61 (44, 76) 0.10
Diabetes, % 8.4 17.0 0.06
Hypertension, % 17.8 57.6 0.001
3-vessel disease, % 2.3 10.1 0.002
LVEF, % 60 (45, 72) 60 (28, 70) 0.02
Lesion length, mm 12.6 (5.7, 22.3) 14.8 (6.5, 28.8) 0.005
Percent stenosis
DD 23.8 (6.4, 71.7) 46.1 (14.1, 64.6) 0.003
DI 27.2 (7.1, 56.8) 28.5 (0.2, 63.2) 0.86
II 27.3 (7.6, 75.6) 29.8 (8.9, 77.8) 0.95
50% restenosis, %
DD 11.6 40.0 0.006
DI 11.7 6.9 0.75
II 15.1 21.4 0.67
Late loss, mm
DD 0.63 (0.27, 1.97) 1.24 (0.16, 2.05) 0.05
DI 0.63 (0.13, 1.74) 0.67 (0.08, 1.48) 0.46
II 0.67 (0.0, 1.90) 0.64 (0.21, 2.53) 0.77
All continuous variables are expressed as median values. The numbers in parentheses
are the 5th and 95th percentiles.
ACE  angiotensin-converting enzyme; DD  homozygotes with two deletion
alleles in the ACE gene; DI  heterozygotes with one deletion and one insertion
allele in the ACE gene; II homozygotes with two insertion alleles in the ACE gene;
Late loss  postprocedure minimal lumen diameter minus minimal lumen diameter
at follow-up; LVEF  left ventricular ejection fraction.
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significantly greater late lumen loss was demonstrated in
patients with the D-allele, whereas the diameter stenosis
and restenosis rate only tended to be higher in this group of
patients. Ribichini et al. (27) examined 176 patients of
whom 20% had angiographic restenosis six months after
stent implantation. In addition to a higher late lumen loss,
patients with the D-allele of the ACE genotype had a
higher frequency of in-stent restenosis. In that study, in
which no patients were on ACE inhibitor treatment, an
association between the ACE plasma concentration levels
and the rate of in-stent restenosis was suggested.
In 1,850 unselected patients undergoing percutaneous
transluminal coronary angioplasty (PTCA) and stent im-
plantation for a variety of indications, Koch et al. (28) found
no association between the D/I polymorphism of the ACE
gene and in-stent restenosis. The frequency of in-stent
restenosis in the latter study was rather high (33%), as was
the percentage of the patients treated with ACE inhibitors
(DD: 54.3%, DI: 52.3%, II: 49.1%). In addition, there were
significant differences in several baseline parameters between
the ACE genotype groups. In the DD genotype group, there
was a higher frequency of elderly, female and diabetic
patients and more patients with unstable angina and mul-
tivessel disease. Although not directly comparable because
of differences in patient characteristics and methodology,
the results of our study confirm those of Koch et al. (28).
The conflicting findings in studies evaluating the influ-
ence of the D/I polymorphism on the development of
coronary in-stent restenosis might be caused by ethnic
differences in the expression of the D/I polymorphism and
interactions with other genes or lifestyle factors, as has been
suggested for myocardial infarction and restenosis after
balloon angioplasty (20,29).
ACE inhibitor treatment and restenosis. Although ani-
mal studies have suggested a role of ACE inhibitors, large,
randomized trials of ACE inhibitor treatment after coro-
nary artery balloon angioplasty have found no effect on the
development of restenosis (9–11). However, the formation
of restenosis after balloon angioplasty is a complex process
involving both recoil of the vessel and cell migration/
proliferation, whereas in-stent restenosis is almost solely a
result of neointimal growth (13–15). Angiotensin-
converting enzyme inhibitors and angiotensin receptor an-
tagonists, which are drugs widely used in patients with
ischemic heart disease, were taken by 15% of patients in our
study (Table 4). A post hoc analysis was performed to
evaluate the potential of these drugs in reducing in-stent
restenosis. Unexpectedly, a strong tendency towards higher
in-stent diameter stenosis, late loss and frequency of resten-
osis was found in drug-treated patients. This may be
explained by a higher frequency of risk factors such as
diabetes, hypertension and longer coronary artery lesions in
these patients (Table 3). Thus, a possible preventive effect of
ACE inhibitors and angiotensin receptor antagonists on
development of in-stent restenosis did not outweigh the
impact of these risk factors, and, accordingly, an accelerat-
ing effect on in-stent restenosis of these drugs cannot be
ruled out (Table 4).
DD genotype, ACE inhibitors and restenosis. In our
subanalysis of patients on ACE inhibitors or angiotensin
receptor antagonists, an increased rate of in-stent restenosis
was confined to the DD genotype group suggesting a
protective role of the I-allele. However, this kind of post hoc
analysis should be evaluated with extreme caution, and
further studies are needed to evaluate this issue. On the
other hand, a randomized study by Okamura et al. (30)
demonstrated that DD genotype patients treated with
imidapril (an ACE inhibitor) compared with control sub-
jects had a higher restenosis rate after balloon angioplasty. In
addition, a recent randomized, double-blind, placebo-
controlled study by Meurice et al. (31) of 91 DD genotype
patients treated with the ACE inhibitor quinapril reported an
increase in late lumen loss in the quinapril-treated patients.
Predictors of restenosis. Regression analysis of our data also
showed that a history of diabetes, the lesion length before stent
implantation and the minimal lumen diameter immediately
after stent implantation are significant, and clinically relevant,
independent predictors of in-stent restenosis (32–36). In the
regression analysis, we found no independent impact of the
DD genotype (Table 3). This finding does not exclude a small
independent effect of the ACE gene polymorphism, but this is
of no apparent clinical relevance.
Study limitations and implications. Given the limited
size of our study, the findings that patients in the DD
genotype group treated with ACE inhibitors or angiotensin
2 receptor antagonists have an increased rate of in-stent
restenosis should not lead to an immediate change in
established indications and clinically well motivated pre-
scribing of these drugs after PTCA. However, taken to-
gether with the results of other studies, our findings under-
score the need for a large trial to answer these questions
definitively.
Conclusions. The ACE D/I genotype was not an inde-
pendent predictor of in-stent restenosis, and, in general,
there is no reason to test for this polymorphism when
planning percutaneous coronary interventions with stent
implantation. In patients treated with ACE inhibitors or
angiotensin receptor antagonists, the rate of in-stent resten-
osis was increased, particularly in those with a DD geno-
type. This finding requires further study.
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